Free Trial
NASDAQ:GRTX

Galera Therapeutics (GRTX) Stock Price, News & Analysis

$0.14
0.00 (-1.75%)
(As of 02:15 PM ET)
Today's Range
$0.13
$0.14
50-Day Range
$0.08
$0.23
52-Week Range
$0.07
$3.09
Volume
58,898 shs
Average Volume
1.80 million shs
Market Capitalization
$7.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
GRTX stock logo

About Galera Therapeutics Stock (NASDAQ:GRTX)

Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.

GRTX Stock Price History

GRTX Stock News Headlines

Galera Therapeutics (NASDAQ:GRTX) Shares Up 7.4%
This student turned $1,300 into $45,000 in just 4 Months!
With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... In fact, it just detected a move happening this MONDAY.
This student turned $1,300 into $45,000 in just 4 Months!
With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... In fact, it just detected a move happening this MONDAY.
GRTX Apr 2024 0.500 call
Galera Therapeutics, Inc. (GRTX)
Galera Therapeutics, Inc.
Galera Therapeutics Inc (GRTX)
See More Headlines
Receive GRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/13/2024
Today
7/15/2024
Next Earnings (Estimated)
8/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GRTX
Fax
N/A
Employees
7
Year Founded
N/A

Profitability

Net Income
$-59,080,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($2.41) per share

Miscellaneous

Free Float
50,639,000
Market Cap
$7.61 million
Optionable
Optionable
Beta
1.98
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. J. Mel Sorensen M.D. (Age 67)
    CEO, President & Director
    Comp: $632.64k
  • Dr. Robert A. Beardsley M.B.A. (Age 62)
    Ph.D., Co-Founder & COO
    Comp: $464.59k
  • Mr. Christopher Degnan (Age 44)
    Chief Financial Officer
    Comp: $474.05k
  • Ms. Jennifer Evans Stacey Esq. (Age 59)
    Chief Legal & Compliance Officer and Secretary
  • Ms. Andie Collier
    Chief Regulatory & Quality Affairs Officer
  • Ms. Judy Schnyder
    Senior Vice President of Clinical Operations & Data Management

GRTX Stock Analysis - Frequently Asked Questions

How have GRTX shares performed this year?

Galera Therapeutics' stock was trading at $0.1454 at the beginning of the year. Since then, GRTX shares have decreased by 3.7% and is now trading at $0.14.
View the best growth stocks for 2024 here
.

How were Galera Therapeutics' earnings last quarter?

Galera Therapeutics, Inc. (NASDAQ:GRTX) released its earnings results on Monday, May, 13th. The company reported ($0.08) EPS for the quarter.

When did Galera Therapeutics IPO?

Galera Therapeutics (GRTX) raised $75 million in an initial public offering on Thursday, November 7th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Citigroup and Credit Suisse served as the underwriters for the IPO and BTIG was co-manager.

How do I buy shares of Galera Therapeutics?

Shares of GRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Galera Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Galera Therapeutics investors own include Fulcrum Therapeutics (FULC), Ardelyx (ARDX), Chiasma (CHMA), Provention Bio (PRVB) and Seelos Therapeutics (SEEL).

This page (NASDAQ:GRTX) was last updated on 7/15/2024 by MarketBeat.com Staff

From Our Partners